Head to Head Analysis: Mereo BioPharma Group (NASDAQ:MREO) & Spruce Biosciences (NASDAQ:SPRB)

Spruce Biosciences (NASDAQ:SPRB – Get Free Report) and Mereo BioPharma Group (NASDAQ:MREO – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations.

Insider and Institutional Ownership

91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are held by institutional investors. 4.3% of Spruce Biosciences shares are held by insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Spruce Biosciences and Mereo BioPharma Group, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spruce Biosciences 1 0 11 0 2.83
Mereo BioPharma Group 2 3 3 0 2.12

Spruce Biosciences presently has a consensus price target of $158.22, indicating a potential upside of 277.99%. Mereo BioPharma Group has a consensus price target of $1.67, indicating a potential upside of 503.86%. Given Mereo BioPharma Group’s higher probable upside, analysts plainly believe Mereo BioPharma Group is more favorable than Spruce Biosciences.

Valuation and Earnings

This table compares Spruce Biosciences and Mereo BioPharma Group”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Spruce Biosciences N/A N/A -$38.97 million ($33.71) -1.24
Mereo BioPharma Group $500,000.00 88.15 -$41.88 million ($0.04) -6.90

Spruce Biosciences has higher earnings, but lower revenue than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Spruce Biosciences has a beta of 3.57, meaning that its share price is 257% more volatile than the S&P 500. Comparatively, Mereo BioPharma Group has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500.

Profitability

This table compares Spruce Biosciences and Mereo BioPharma Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Spruce Biosciences N/A -118.22% -88.36%
Mereo BioPharma Group N/A -84.62% -71.44%

About Spruce Biosciences

(Get Free Report)

Spruce Biosciences is a biotechnology company focused on developing treatments for rare endocrine disorders. The U.S.-based company has concentrated on conditions with limited treatment options and has advanced oral drug candidates through clinical development. Its lead investigational candidate, tildacerfont, is a corticotropin-releasing factor type 1 receptor antagonist that Spruce studied for congenital adrenal hyperplasia, a rare disorder affecting hormone production. The company also evaluated the candidate for other endocrine conditions, including polycystic ovary syndrome.

About Mereo BioPharma Group

(Get Free Report)

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases and cancer. Established in 2015 and based in the United Kingdom, the company advances drug candidates that it has acquired or licensed from other pharmaceutical developers. Its rare-disease programs include setrusumab, an investigational antibody being developed for osteogenesis imperfecta, and alvelestat, an investigational oral drug being studied for lung disease associated with alpha-1 antitrypsin deficiency.

Receive News & Ratings for Spruce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spruce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.